D M Gibb

Summary

Affiliation: National Institute for Medical Research
Country: UK

Publications

  1. ncbi Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial
    Diana M Gibb
    Medical Research Counsel Clinical Trials Unit, London, UK
    Pediatr Infect Dis J 22:56-62. 2003
  2. ncbi Active surveillance of hepatitis C infection in the UK and Ireland
    D M Gibb
    Department of Epidemiology and Public Health, Institute of Child Health, London, UK
    Arch Dis Child 82:286-91. 2000
  3. ncbi Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission
    D M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Lancet 356:904-7. 2000
  4. ncbi Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection
    Diana M Gibb
    Medical Research Council Trials Unit, London, UK
    Pediatr Infect Dis J 23:446-50. 2004
  5. ncbi Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland
    D M Gibb
    Medical Research Council Clinical Trials Unit, London NW1 2DA
    BMJ 327:1019. 2003
  6. ncbi Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Diana M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 7:293-303. 2002
  7. ncbi Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
  8. ncbi Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
    P Mugyenyi
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:123-31. 2010
  9. ncbi Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection
    D T Dunn
    Medical Research Council Clinical Trials Unit, Institute of Child Health, London, UK
    Pediatr Infect Dis J 20:715-6. 2001
  10. ncbi Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort
    A S Walker
    MRC Clinical Trials Unit, London, UK
    Lancet 375:1278-86. 2010

Detail Information

Publications48

  1. ncbi Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial
    Diana M Gibb
    Medical Research Counsel Clinical Trials Unit, London, UK
    Pediatr Infect Dis J 22:56-62. 2003
    ..Most studies of adherence to highly active antiretroviral therapy in children have been retrospective or cross-sectional. Factors relating to the caregiver, the child and the medication are all considered to be important for good adherence...
  2. ncbi Active surveillance of hepatitis C infection in the UK and Ireland
    D M Gibb
    Department of Epidemiology and Public Health, Institute of Child Health, London, UK
    Arch Dis Child 82:286-91. 2000
    ..To investigate the prevalence, distribution, and clinical details of paediatric hepatitis C virus (HCV) infection in the UK and Ireland...
  3. ncbi Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission
    D M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Lancet 356:904-7. 2000
    ..We examined the effect of risk factors, including mode of delivery, on the vertical transmission rate...
  4. ncbi Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection
    Diana M Gibb
    Medical Research Council Trials Unit, London, UK
    Pediatr Infect Dis J 23:446-50. 2004
    ..There are few data on the decline of CD4 cells or percentage during unplanned treatment interruptions in HIV-infected children...
  5. ncbi Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland
    D M Gibb
    Medical Research Council Clinical Trials Unit, London NW1 2DA
    BMJ 327:1019. 2003
    ..To describe changes in demographic factors, disease progression, hospital admissions, and use of antiretroviral therapy in children with HIV...
  6. ncbi Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)
    Diana M Gibb
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 7:293-303. 2002
    ....
  7. ncbi Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children
    H Green
    MRC Clinical Trials Unit, 222 Euston Road, London, NW1 2DA, UK
    AIDS 21:947-55. 2007
    ..To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial...
  8. ncbi Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
    P Mugyenyi
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:123-31. 2010
    ..This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa...
  9. ncbi Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection
    D T Dunn
    Medical Research Council Clinical Trials Unit, Institute of Child Health, London, UK
    Pediatr Infect Dis J 20:715-6. 2001
    ..These estimates may assist clinicians in assessing the likelihood of infection in an individual child and in using the currently available assays cost effectively...
  10. ncbi Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort
    A S Walker
    MRC Clinical Trials Unit, London, UK
    Lancet 375:1278-86. 2010
    ..We estimated the effect of prophylaxis after ART initiation in adults...
  11. ncbi Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection
    A J Williams
    Department of Epidemiology and Public Health, Institute of Child Health, London, UK
    AIDS 15:335-9. 2001
    ..Breast-feeding increases the risk of combined PCP and CMV infection, which is associated with severe disease...
  12. ncbi Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children
    K Boyd
    Medical Research Council Clinical Trials Unit, London, UK
    AIDS 24:1213-7. 2010
    ..This leads to clinical dilemma when one marker is below the threshold, whereas the other is above...
  13. ncbi PENTA guidelines for the use of antiretroviral therapy, 2004
    M Sharland
    Paediatric Infectious Diseases Unit, St George s Hospital, London, UK
    HIV Med 5:61-86. 2004
    ..Regular formal assessment of adherence is now the standard of care, and routine monitoring in the clinic for lipodystrophy syndrome (LDS) and other ART toxicities is increasingly important. These guidelines will be updated again in 2006...
  14. ncbi First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
    Abdel Babiker
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet Infect Dis 11:273-83. 2011
    ..We assess the long-term outcome of protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI) first-line ART and viral load switch criteria in children...
  15. ncbi The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children
    A Sarah Walker
    MRC Clinical Trials Unit, London, United Kingdom
    Clin Infect Dis 44:1361-7. 2007
    ..Data on the population effectiveness of cotrimoxazole prophylaxis and antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected African children are few...
  16. ncbi A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial
    Hannah Green
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 11:857-67. 2006
    ..To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure...
  17. ncbi HIV drug resistance testing: is the evidence really there?
    David T Dunn
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 9:641-8. 2004
    ..To assess the strength of evidence supporting the routine use of HIV drug resistance testing...
  18. ncbi Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?
    Katherine J Lee
    MRC Clinical Trials Unit, London, UK
    Antivir Ther 12:949-56. 2007
    ..To investigate transient increases in viral load during sustained suppression in children in the UK and Ireland Collaborative HIV Paediatric Study (CHIPS)...
  19. ncbi Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial
    A Sarah Walker
    MRC Clinical Trials Unit, London, UK
    J Acquir Immune Defic Syndr 42:637-45. 2006
    ..There are few data on predictors of HIV progression in untreated children in resource-limited settings...
  20. ncbi Monitoring of highly active antiretroviral therapy in HIV infection
    A Sarah Walker
    MRC Clinical Trials Unit, London, UK
    Curr Opin Infect Dis 24:27-33. 2011
    ..We review studies describing the outcomes and costs of different monitoring approaches, predominantly in low-income countries...
  21. ncbi Economic issues in the prevention of vertical transmission of HIV
    A E Ades
    Department of Epidemiology and Public Health, Institute of Child Health, London, England
    Pharmacoeconomics 18:9-22. 2000
    ....
  22. ncbi Factors affecting uptake of antenatal HIV testing in London: results of a multicentre study
    D M Gibb
    Department of Epidemiology and Public Health, Institute of Child Health, London
    BMJ 316:259-61. 1998
    ..To measure the uptake of antenatal HIV testing and determine its relation to risk of HIV and to screening practices...
  23. ncbi PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS
    M Sharland
    Paediatric Infectious Diseases Unit, St George s Hospital, London, UK
    HIV Med 3:215-26. 2002
    ..To produce European Guidelines for the use of antiretroviral therapy (ART) in HIV-infected children...
  24. ncbi Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy
    Marietta Charakida
    Vascular Physiology Unit, Institute of Child Health, London, UK
    Circulation 112:103-9. 2005
    ..The purpose of this study was to determine the impact of HIV infection and antiretroviral therapy (ART) on markers of early vascular disease in children...
  25. ncbi A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease
    Helen E Harris
    Immunisation Department, Health Protection Agency, Centre for Infections, London, UK
    J Pediatr Gastroenterol Nutr 45:335-41. 2007
    ..To describe hepatitis C virus (HCV)-related liver disease in a national cohort of patients who acquired their infections in childhood or adolescence and to assess risk factors for progressive disease and response to antiviral therapy...
  26. ncbi Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets
    Rafaëlla F A L'homme
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    AIDS 22:557-65. 2008
    ..We determined whether this ratio results in optimal exposure in the target population...
  27. ncbi The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia
    Mairin Ryan
    National Centre for Pharmacoeconomics, Department of Pharmacology and Therapeutics, Trinity College, Dublin, Ireland
    AIDS 22:749-57. 2008
    ....
  28. ncbi Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008
    ....
  29. ncbi Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children
    Marthe LePrevost
    Family Clinic, North West London NHS Trust, London, United Kingdom
    Pediatr Infect Dis J 25:533-7. 2006
    ..CONCLUSION: Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily...
  30. ncbi Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1
    Catherine Litalien
    Department of Pediatric Pharmacology and Pharmacogenetics, , Paris, France
    Pediatr Infect Dis J 22:48-55. 2003
    ..The mechanisms underlying such differences may involve higher first past metabolism and/or drug interactions or might be related to feeding conditions...
  31. ncbi Biphasic decay of cell-associated HIV-1 DNA in HIV-1-infected children on antiretroviral therapy
    Anita De Rossi
    Department of Oncology and Surgical Sciences, AIDS Reference Centre, Padova, Italy
    AIDS 16:1961-3. 2002
  32. ncbi Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial
    Deenan Pillay
    Public Health Laboratory Service Antiviral Susceptibility Reference Unit, Birmingham Public Health Laboratory, Birmingham, United Kingdom
    J Infect Dis 186:617-25. 2002
    ..No differences were observed in the frequency of development of resistance mutations L90M (P=1.00) and D30N (P=.61) in B and non-B viruses. In conclusion, no evidence that subtype determined virologic response to therapy was found...
  33. ncbi Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial
    Anita De Rossi
    Department of Oncology and Surgical Sciences, AIDS Reference Center, Padova, Italy
    J Infect Dis 186:312-20. 2002
    ..Thymic output appears to be the main source of CD4 cell repopulation in children receiving ART. Recovery of thymic function is independent of age and influenced by the status of peripheral CD4 cell depletion and HIV-1 suppression...
  34. ncbi Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study
    A Sarah Walker
    AIDS 18:1915-24. 2004
    ..Differences in response to HAART according to age and underlying risk of disease progression should be considered when initiating HAART in children...
  35. ncbi Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe
    Sylvia K Muyingo
    MRC Uganda Research Unit on AIDS, Entebbe, Uganda
    J Acquir Immune Defic Syndr 48:468-75. 2008
    ..Good adherence is essential for successful antiretroviral therapy (ART) provision, but simple measures have rarely been validated in Africa...
  36. ncbi Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults
    Rafaëlla F A L'homme
    Department of Clinical Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands
    J Antimicrob Chemother 59:92-6. 2007
    ..We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products...
  37. ncbi Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children
    Veronica Mulenga
    University Teaching Hospital, Lusaka, Zambia
    AIDS 21:77-84. 2007
    ..Cotrimoxazole prophylaxis reduces morbidity and mortality in HIV-1-infected children, but mechanisms for these benefits are unclear...
  38. ncbi Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study
    Esse N Menson
    MRC Clinical Trials Unit, London NW1 2DA
    BMJ 332:1183-7. 2006
    ..CONCLUSIONS: Largely inadvertently, HIV infected children in the United Kingdom and Ireland have been underdosed with antiretrovirals, highlighting problems applicable throughout paediatric prescribing...
  39. ncbi Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial
    Francis Ssali
    Joint Clinical Research Centre, Kampala, Uganda
    Antivir Ther 11:741-9. 2006
    ..Clinical vigilance and haemoglobin measurements 4, 8 and 12 weeks after starting zidovudine could help to manage serious anaemia...
  40. ncbi Increasing antiretroviral drug access for children with HIV infection
    Peter L Havens
    Pediatrics 119:838-45. 2007
    ....
  41. ncbi Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy
    Ben Kikaire
    MRC UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
    AIDS 21:733-7. 2007
    ..To measure nevirapine elimination in African adults undertaking a structured treatment interruption (STI) in the DART trial...
  42. ncbi Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy
    Katja Doerholt
    St. Peter's Hospital, Chertsey
    Pediatr Infect Dis J 25:420-6. 2006
    ..Poor virologic response to ART during infancy is of concern because of increased likelihood of early development of resistance...
  43. ncbi Relationship between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1-infected children initiating antiretroviral therapy
    Anita De Rossi
    Department of Oncology and Surgical Sciences, AIDS Reference Centre, Padova, Italy
    Antivir Ther 10:63-71. 2005
    ....
  44. ncbi Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia
    Jane C Ellis
    Department of Paediatrics, College of Medicine, Blantyre, Malawi
    Antivir Ther 12:253-60. 2007
    ..To investigate nevirapine concentrations in African HIV-infected children receiving divided Triomune tablets (stavudine+lamivudine+nevirapine)...
  45. ncbi Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy
    Andrew Reid
    University of Zimbabwe, Harare, Zimbabwe
    Clin Infect Dis 46:1271-81. 2008
    ..We sought to investigate renal function in previously untreated symptomatic human immunodeficiency virus (HIV)-infected adults with CD4(+) cell counts of <200 cells/mm(3) who were undergoing antiretroviral therapy (ART) in Africa...
  46. ncbi HIV disease and respiratory infection in children
    Stephen M Graham
    Wellcome Trust Research Laboratory and Department of Paediatrics, College of Medicine, University of Malawi, Malawi
    Br Med Bull 61:133-50. 2002
    ....
  47. ncbi Clinical trials in children
    Esse N Menson
    Lancet 364:2176-7. 2004